An observational study in PSP, CBD and PCA, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Mayo Clinic · Observational
The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.
The investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. Participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. At each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an MRI, an FDG PET/CT scan, a PiB PET/CT scan, a Tau PET/CT scan and/or a C-11 ER176 PET/CT scan. All participants will be asked to provide a blood sample to allow for future genetic studies.
208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.
This study's planned enrollment of 500 is above the median of 200 across 73 observational studies indexed under Frontotemporal Dementia.
Browse Frontotemporal Dementia studies →Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Symptoms of neurodegenerative disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: C-11 PiB · Drug: AV1451 Tau · Drug: C-11 ER176
Completing PET scan looking for amyloid protein
Completing PET scan looking for tau protein
Completing PET scan looking for neuroinflammation
Imaging analysis
Longitudinal images and correlates will be measured and tracked to determine direct correlations in the brain with disease progression on a yearly basis
Time frame: 1 year
Plan to share: Undecided
Started Nov 2020 (actual). Primary completion is estimated for Nov 2050, 360 months after the start.
Of 46 observational studies under Frontotemporal Dementia, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 44. This study's planned 360 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.